Lonza Group logo

Lonza Group

Stock
Stock
ISIN: CH0013841017
Ticker: LONN
CH0013841017
LONN

Price

Price

CHART BY

Historical dividends and forecast

All dividend data

Lonza Group has so far distributed $6.354 in 2026. The next dividend will be paid on 15.05.2027


$2.938

CHART BY

Frequently asked questions

The market capitalization of Lonza Group is 38.11B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Lonza Group's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.539. EPS indicates the company's profitability on a per-share basis.
Currently, 28 analysts cover Lonza Group's stock, with a consensus target price of 682.92. Analyst ratings provide insights into the stock's expected performance.
Over the trailing twelve months, Lonza Group reported a revenue of 6.33B.
Lonza Group's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is 2.15B. EBITDA measures the company's overall financial performance.
Lonza Group has a free cash flow of 215.00M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Lonza Group employs approximately 16,866 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Lonza Group is 69.40M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
38.11B
EPS (TTM) 
-$1.539
Free Float 
69.40M
Revenue (TTM) 
6.33B
EBITDA (TTM) 
2.15B
Free Cashflow (TTM) 
215.00M

Pricing

1D span
$665.56$672.75
52W span
$578.19$763.23

Analyst Ratings

The price target is 682.92 and the stock is covered by 28 analysts.

Buy

24

Hold

3

Sell

1

Information

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Employees
16,866
Industries
Biotechnology
Sector
Health Care

Identifier

ISIN
CH0013841017
Primary Ticker
LONN

Knockouts

Real-time data from LSX · Fundamentals & EOD data from FactSet
Join the conversation